Literature DB >> 6247360

Elevated nephrogenous cyclic AMP with normal serum parathyroid hormone levels in patients with lung cancer.

S C Kukreja, W P Shemerdiak, T E Lad, P A Johnson.   

Abstract

Total and nephrogenous urinary cyclic AMP (cAMP), serum Parathyroid Hormone (PTH) and ionized calcium (Ca) levels were determined in 8 normal subjects, and 16 normocalcemic and 9 hypercalcemic patients with lung cancer. Total and nephrogeneous cAMP levels were significantly increased in both normocalcemic and hypercalcemic lung cancer patients, as compared to normal subjects. There was no significant correlation between serum PTH and total or nephrogenous cAMP in the cancer group. The factors responsible for the elevated nephrogenous cAMP in the lung cancer patients are not known.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6247360     DOI： 10.1210/jcem-51-1-167

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


  13 in total

Review 1.  Hypercalcemia of malignancy.

Authors:  V Grill; T J Martin
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Influence of pregnancy on immunoreactive parathyroid hormone levels.

Authors:  M E Gillette; K L Insogna; A M Lewis; D T Baran
Journal:  Calcif Tissue Int       Date:  1982-01       Impact factor: 4.333

3.  Parathyroid hormone-related protein of malignancy: immunohistochemical and biochemical studies in normocalcaemic and hypercalcaemic patients with cancer.

Authors:  S H Ralston; J Danks; J Hayman; W D Fraser; C S Stewart; T J Martin
Journal:  J Clin Pathol       Date:  1991-06       Impact factor: 3.411

4.  Humoral hypercalcemia of malignancy. Release of a prostaglandin-stimulating bone-resorbing factor in vitro by human transitional-cell carcinoma cells.

Authors:  F R Bringhurst; B E Bierer; F Godeau; N Neyhard; V Varner; G V Segre
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

Review 5.  Current management of malignant hypercalcaemia.

Authors:  J C Stevenson
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

6.  Plasma cyclic nucleotide levels in patients with refractory anaemia with excess of blasts.

Authors:  M Peracchi; F Bamonti-Catena; B Bareggi; R Calori; A T Maiolo
Journal:  Blut       Date:  1990-03

7.  PTHrP(12-48) Modulates the Bone Marrow Microenvironment and Suppresses Human Osteoclast Differentiation and Lifespan.

Authors:  Archana Kamalakar; Charity L Washam; Nisreen S Akel; Bethany J Allen; Diarra K Williams; Frances L Swain; Kim Leitzel; Allan Lipton; Dana Gaddy; Larry J Suva
Journal:  J Bone Miner Res       Date:  2017-04-19       Impact factor: 6.741

Review 8.  Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine.

Authors:  Laurie K McCauley; T John Martin
Journal:  J Bone Miner Res       Date:  2012-05-01       Impact factor: 6.741

9.  Identification of adenylate cyclase-stimulating activity and cytochemical glucose-6-phosphate dehydrogenase-stimulating activity in extracts of tumors from patients with humoral hypercalcemia of malignancy.

Authors:  A F Stewart; K L Insogna; D Goltzman; A E Broadus
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

10.  A model for malignancy-associated humoral hypercalcemia.

Authors:  E C Abramson; L J Kukla; D H Shevrin; T E Lad; W P McGuire; S C Kukreja
Journal:  Calcif Tissue Int       Date:  1984-09       Impact factor: 4.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.